Research chemicalResearch chemicalDissociativeArylcyclohexylamine

3-MeO-PCE

Also known as 3-MeO-PCE · Methoxieticyclidine

Written by enwyReviewed 4 Aug 20262 sources0 comments

3-MeO-PCE (methoxieticyclidine) is a potent, highly stimulating arylcyclohexylamine dissociative sold as a research chemical. It is reported as one of the more manic and psychosis-prone dissociatives, with very little human data.

01 Overview

3-MeO-PCE is the eticyclidine analogue corresponding to 3-MeO-PCP, combining NMDA antagonism with strong stimulation. Users describe an intense, manic, sometimes disorganising experience, and it is regarded within harm-reduction communities as one of the more unpredictable and psychosis-prone dissociatives.

There is essentially no clinical literature. Reported harms are anecdotal and centre on agitation, mania, psychosis and cardiovascular stimulation, with a narrow margin between active and excessive doses.

02 Mechanism

Potent NMDA-receptor antagonist with pronounced stimulating activity, likely involving monoamine effects analogous to 3-MeO-PCP.

03 Dosing

Tier	Dose	Route	Notes
Threshold	2–4 mg	Oral
Common	3–8 mg	Insufflated
Common	5–12 mg	Oral	Potent and unpredictable; narrow margin.

04 Effects

Effect	Magnitude	Evidence
Stimulating dissociationEnergetic, manic dissociation.		Anecdotal
AnalgesiaPain relief typical of the class.		Anecdotal

05 Side effects

Effect	Severity	Frequency	Evidence	Countermeasures
Psychosis and maniaMania, paranoia and psychosis reported, sometimes at moderate doses.	Severe	Reported at moderate-high doses	Anecdotal
Cardiovascular stimulation and overdoseTachycardia, hypertension and agitation; narrow dose margin.	Severe	Common at high doses	Anecdotal

06 Legal status

United States

Possibly controlled as an analogue

May fall under the Federal Analogue Act. · as of Jan 2026

United Kingdom

Class B controlled drug

Controlled as an arylcyclohexylamine. · as of Jan 2026

07 References

3-MeO-PCE reports and characterisationPubMed literature

New psychoactive substances: dissociativesEUDA (European Union Drugs Agency)

08 Discussion0 comments

Create account

Discussion is moderated. No sourcing, vendor names or price talk — those comments are removed, and repeat posts are banned.

This page is reference information, not medical advice. Doses and protocols are documented as they appear in the clinical literature and in practice — describing them is not a recommendation to use them. Countermeasures listed here are not a substitute for a physician. Legal status varies by jurisdiction and changes.